Loss of YAP completely inhibited LKB1 deficient lung adenocarcinoma growth in vivo, indicating YAP as the critical mediator of oncogenic effects of LKB1 inactivation and YAP antagonism may represent a therapeutic approach for LKB1 mutant tumors. This evidence concerns the gene STK11 and lung adenocarcinoma.